Capital One Initiates Coverage On Outlook Therapeutics with Overweight Rating, Announces Price Target of $5
Portfolio Pulse from richadhand@benzinga.com
Capital One analyst Zegbeh Jallah has initiated coverage on Outlook Therapeutics (NASDAQ:OTLK) with an Overweight rating and a price target of $5.
July 13, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics has received an Overweight rating from Capital One, with a price target of $5.
The Overweight rating from Capital One indicates a positive outlook for Outlook Therapeutics. The price target of $5 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100